Key Financials Snapshot

TTM · Consolidated · ₹ in Cr
Market Cap
₹1975 Cr.
Stock P/E
63.2
P/B
4.2
Current Price
₹28.3
Book Value
₹ 6.7
Face Value
1
52W High
₹121.5
52W Low
₹ 28.1
Dividend Yield
0.18%

Fischer Medical Overview

Business

Fischer Medical Ventures Ltd. is an Indian company primarily engaged in the trading, manufacturing, and refurbishment of medical devices and equipment. Its core business revolves around providing a comprehensive range of medical solutions. They deal in new and refurbished medical imaging equipment (such as MRI, CT scanners, Ultrasound, X-ray machines), critical care equipment, and other medical consumables. Through its subsidiary, Fischer Surgical Private Limited, the company also manufactures surgical gowns, drapes, and other medical textiles. Additionally, it offers repair and maintenance services for various medical equipment. The company generates revenue through sales margins on traded and manufactured goods, refurbishment services, and service contracts.

Revenue Mix

While specific percentage breakdowns are not always publicly detailed for an SME company, Fischer Medical Ventures Ltd.'s revenue streams primarily originate from:

Trading of Medical Equipment: This includes both new and refurbished high-value medical imaging equipment and other devices, often imported.

Manufacturing: Production and sales of medical consumables like surgical gowns and drapes.

Services: Repair, maintenance, and installation services for medical equipment.

The refurbishment of medical imaging equipment is a significant aspect, providing a cost-effective alternative to new equipment.

Industry

The company operates within the rapidly growing Indian medical devices market. This market is driven by increasing healthcare expenditure, expansion of healthcare infrastructure (hospitals, diagnostic centers), medical tourism, and government initiatives. The industry is characterized by a mix of large multinational players, domestic manufacturers, and a fragmented distribution network.

Fischer Medical Ventures Ltd. positions itself as a niche player by combining distribution of new equipment with a strong focus on refurbishment services. This allows them to cater to a diverse clientele, including smaller hospitals, diagnostic centers, and those in tier 2/3 cities seeking cost-effective yet reliable medical technology. They compete with direct manufacturers, larger distributors, and other refurbishment service providers.

MOAT

Fischer Medical Ventures Ltd. possesses a competitive advantage primarily through:

Refurbishment Capability: Their in-house facility for refurbishing high-value medical imaging equipment allows them to offer advanced technology at a significantly lower cost, catering to a price-sensitive market segment. This creates a distinct value proposition.

Integrated Model: The combination of trading new equipment, trading refurbished equipment, manufacturing select consumables, and providing service creates a more comprehensive offering and potential customer stickiness.

Distribution & Service Network: For a trading company, established relationships with both international suppliers and a growing network of domestic healthcare providers are crucial, enhancing market reach and customer loyalty through reliable post-sales support.

Growth Drivers

Expanding Indian Healthcare Sector: Continued growth in healthcare spending, demand for diagnostics, and expansion of hospitals and clinics nationwide.

Demand for Cost-Effective Solutions: The increasing need for affordable healthcare solutions, particularly in non-metro areas, drives demand for quality refurbished equipment.

"Make in India" Initiative: Their manufacturing of medical consumables aligns with government initiatives promoting domestic production, potentially leading to increased demand and favorable policies.

Product Portfolio and Geographic Expansion: Introduction of new products and services, along with expanding their sales and service network to new regions, can drive market penetration.

Aging Equipment Base: As existing medical equipment ages, the demand for replacement, upgrades, and refurbishment services naturally increases.

Risks

Regulatory Risks: The medical device industry in India is subject to stringent and evolving regulations (e.g., CDSCO guidelines, quality standards). Changes can impact import, manufacturing, and sales.

Foreign Exchange Fluctuations: Significant reliance on imported equipment (new and used) exposes the company to adverse movements in foreign currency exchange rates.

Intense Competition: The market is competitive with numerous domestic and international players, which can put pressure on margins and market share.

Supply Chain Dependency: Reliance on international suppliers for sourcing both new and used equipment, as well as components for refurbishment, makes them vulnerable to global supply chain disruptions.

Technology Obsolescence: Rapid advancements in medical technology can lead to quicker obsolescence of existing equipment, impacting inventory value and refurbishment demand.

Working Capital Management: High-value inventory and extended credit periods common in equipment sales necessitate efficient working capital management.

Management & Ownership

Fischer Medical Ventures Ltd. is promoted by Mr. Ravilla Kumar (Chairman & Managing Director) and Mrs. Ravilla Mamatha Reddy. Mr. Ravilla Kumar is a key driving force with significant experience in the medical equipment industry, guiding the company's strategic direction. As of the latest available information (e.g., March 2024), the promoter holding in the company is substantial, typically around 73-75%, which is common for SME-listed companies in India, indicating strong management control and alignment of interests.

Outlook

Fischer Medical Ventures Ltd. operates in a promising sector driven by India's growing healthcare needs. Its integrated business model, which combines trading of new and refurbished equipment with manufacturing and services, positions it to capture opportunities across various customer segments, especially the cost-conscious ones. The ability to refurbish high-value medical imaging equipment provides a distinct market advantage. However, the company faces inherent challenges typical for an SME operating in a competitive and highly regulated industry. Key risks include exposure to foreign exchange volatility, intense competition from larger players, and the need for efficient working capital management. Its future growth hinges on effective navigation of regulatory changes, successful expansion of its product portfolio and service network, and sustained operational efficiency amidst these challenges.

Fischer Medical Share Price

Live · BSE / NSE · Inception: 1993
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Consolidated · annual

Fischer Medical Quarterly Results

#(Fig in Cr.) Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 21 10 40 12 49 23 86 101 98 82
Other Income 0 1 0 0 0 7 2 1 1 1
Total Income 21 11 40 12 49 31 89 102 99 83
Total Expenditure 18 10 39 11 47 19 70 80 97 71
Operating Profit 3 0 1 1 3 12 19 23 2 13
Interest 0 0 0 0 0 1 1 1 4 4
Depreciation 0 0 0 1 1 1 1 1 1 1
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 3 0 0 0 2 10 17 21 -2 8
Provision for Tax 0 0 -0 0 1 5 3 2 5 4
Profit After Tax 3 -0 0 -0 1 5 14 19 -7 4
Adjustments 0 0 -0 -0 -0 -0 -0 -0 0 0
Profit After Adjustments 3 -0 0 -0 1 5 14 19 -7 4
Adjusted Earnings Per Share 0 -0 0 -0 0 0.1 0.2 0.3 -0.1 0.1

Fischer Medical Profit & Loss

#(Fig in Cr.) Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Net Sales 0 21 111 309 367
Other Income 0 1 1 12 5
Total Income 0 21 112 321 373
Total Expenditure 0 19 107 265 318
Operating Profit 0 2 5 55 57
Interest 0 0 0 6 10
Depreciation 0 0 2 3 4
Exceptional Income / Expenses 0 0 0 0 0
Profit Before Tax -0 2 3 47 44
Provision for Tax 0 0 1 15 14
Profit After Tax -0 2 2 31 30
Adjustments 0 -0 -1 -1 0
Profit After Adjustments -0 1 1 30 30
Adjusted Earnings Per Share -0.2 0 0 0.5 0.5

Fischer Medical Balance Sheet

#(Fig in Cr.) Mar 2023 Mar 2024 Mar 2025 Mar 2026
Shareholder's Funds -0 81 338 384
Minority's Interest 0 0 0 1
Borrowings 1 0 0 0
Other Non-Current Liabilities -0 1 17 26
Total Current Liabilities 0 4 105 258
Total Liabilities 0 86 461 669
Fixed Assets 0 15 24 32
Other Non-Current Assets 0 1 68 220
Total Current Assets 0 70 369 418
Total Assets 0 86 461 669

Fischer Medical Cash Flow

#(Fig in Cr.) Mar 2023 Mar 2024 Mar 2025 Mar 2026
Opening Cash & Cash Equivalents 0 0 1 104
Cash Flow from Operating Activities 0 -7 -86 -101
Cash Flow from Investing Activities 0 -31 -125 -5
Cash Flow from Financing Activities 0 37 315 14
Net Cash Inflow / Outflow 0 -2 103 -92
Closing Cash & Cash Equivalent 0 1 104 12

Fischer Medical Ratios

# Mar 2023 Mar 2024 Mar 2025 Mar 2026
Earnings Per Share (Rs) -0.21 0.03 0.01 0.46
CEPS(Rs) -0.21 0.04 0.05 0.52
DPS(Rs) 0 0 0.01 0.05
Book NAV/Share(Rs) -1.55 1.5 4.82 5.48
Core EBITDA Margin(%) 8.47 8.86 3.02 13.96
EBIT Margin(%) 8.47 10.38 2.89 16.99
Pre Tax Margin(%) -0.72 10.06 2.45 15.1
PAT Margin (%) -20.33 8.76 1.53 10.12
Cash Profit Margin (%) -20.33 9.63 3.01 11.09
ROA(%) -14.72 4.25 0.62 5.53
ROE(%) 0 4.6 0.87 9.38
ROCE(%) 4.97 5.35 1.34 12.27
Receivable days 346.9 200.41 163.11 215.79
Inventory Days 0 77.86 22.49 12.91
Payable days 0 24.06 45.45 115.01
PER(x) 0 2421.12 6106.8 88.68
Price/Book(x) -5.43 41.65 18.64 7.38
Dividend Yield(%) 0 0 0.01 0.12
EV/Net Sales(x) 11.03 157.47 49.98 8.72
EV/Core EBITDA(x) 130.31 1399.44 1144.14 48.6
Net Sales Growth(%) 0 0 427.61 178.75
EBIT Growth(%) 0 0 47.01 1536.47
PAT Growth(%) 0 5135.34 -7.79 1743.48
EPS Growth(%) 0 112.16 -43.02 3000
Debt/Equity(x) -2.15 0 0.2 0.2
Current Ratio(x) 5.18 18.37 3.5 1.62
Quick Ratio(x) 5.18 17.21 3.41 1.57
Interest Cover(x) 0.92 32.23 6.49 8.98
Total Debt/Mcap(x) 0.4 0 0.01 0.03

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +178% — — —
Operating Profit CAGR +1000% — — —
PAT CAGR +1450% — — —
Share Price CAGR -71% +55% +20% +66%
ROE Average +9% +5% +4% +4%
ROCE Average +12% +6% +6% +6%

Fischer Medical Shareholding Pattern

Latest · Jun 2026
100% held
Promoters 62.15 %
FII 5.48 %
DII (MF + Insurance) 1.35 %
Public (retail) 31.02 %
# Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Promoter 074.9174.9174.9162.8161.861.861.862.1562.15
FII 5.075.075.075.075.235.555.574.854.975.48
DII 1.681.681.681.681.441.421.421.361.381.35
Public 93.2418.3318.3318.3330.5131.2331.2131.9931.531.02
Others 0000000000
Total 100100100100100100100100100100

Fischer Medical Peer Comparison

Fischer Medical Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Fischer Medical Pros & Cons

Pros

  • Company is almost debt free.

Cons

  • Company has a low return on equity of 5% over the last 3 years.
  • Debtor days have increased from 45.45 to 115.01days.
  • Stock is trading at 4.2 times its book value.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp